GBM cells express CD47,38 an antiphagocytic signal that is frequently overexpressed in cancers.39 Combining avelumab with CD47 inhibition strategies,40 several of which are undergoing clinical testing, could be a promising future direction to enhance its ability to directly induce cell killing. This evidence concerns the gene CD47 and cancer.